AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01958879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ringer with corticosteroid
Description: 200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
Study NCT01958879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ringer without corticosteroid
Description: 200 mL Ringer solution
Study NCT03805555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Pulmonary vein isolation by radiofrequency ablation
Study NCT03805555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Pulmonary vein isolation by cryoballoon ablation
Study NCT02770313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
Study NCT01178346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX vaccine
Description: NicVAX vaccine given 6 times over 6 months
Study NCT01178346 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccine given 6 times over 6 months
Study NCT00707343 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLT-PET Imaging
Description: radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
Study NCT00424294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-195,543
Description: CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
Study NCT00424294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
Study NCT00424294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
Study NCT01333306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Study NCT01896388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifenprodil Tartrate
Study NCT01896388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00450619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant vaccinia-TRICOM vaccine
Description: 2 x 10\^8 PFU given subcutaneously on day 1.
Study NCT00450619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fowlpox-TRICOM vaccine
Description: 1 x 10\^9 PFU given subcutaneously on days 15 and 29
Study NCT01688076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Forehead will be injected with Botox.
Study NCT01688076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Description: Forehead will be injected with Botox.
Study NCT04078880 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrosomial iron plus ascorbic acid
Description: A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
Study NCT02287909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Swiching from ticagrelor to clopidogrel
Study NCT02287909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Continue treatment with ticagrelor
Study NCT03279211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate 894 Fonterra
Description: 30 g of protein powder diluted in water
Study NCT03279211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zein Sigma-Aldrich W555025
Description: 30 g of protein powder diluted in water
Study NCT03279211 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Protein-free test-meal
Description: No protein included in the drink made of water and flavour/sugar
Study NCT00874003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirtazapine
Description: oral tablet, 30 mg daily
Study NCT00874003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet, 1 daily
Study NCT03018808 — intervention group
Intervention type: OTHER
Intervention: Minimal questionnaire
Description: The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
Study NCT03018808 — intervention group
Intervention type: OTHER
Intervention: Medical interview
Description: Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
Study NCT00680628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase + Enoxaparin
Description: Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: \<60Kg=30mg; ≥60Kg to \<70Kg=35mg; ≥70Kg to \<80Kg=40mg; ≥80Kg to \<90Kg=45mg; ≥90Kg=50mg
Study NCT00680628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline + Enoxaparin
Description: Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
Study NCT01658553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
Study NCT01864265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
Study NCT01864265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
Study NCT01864265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered according to the label of the biological
Study NCT01864265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered according to the label of the biological
Study NCT00820989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin, Lipopolysaccharide, LPS
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
Study NCT01448538 — intervention group
Intervention type: DRUG
Intervention: Anti-VEGF injections
Description: All Anti-VEGF injections approved for the German market, dosages as defined by doctors
Study NCT03027674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% nifedipine cream
Description: Topical treatment for Raynaud
Study NCT03027674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% sildenafil cream
Description: Topical treatment for Raynaud
Study NCT01452477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tanshinone
Description: tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
Study NCT01452477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tanshinone placebo
Description: placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
Study NCT00827177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with ARQ 197 in combination with sorafenib
Description: Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If \< 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid).
Study NCT00437398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet Transplant
Description: Purified pancreatic islets
Study NCT03486782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IFG stimulation
Description: stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
Study NCT03486782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC stimulation
Description: stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
Study NCT03486782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia therapy
Description: aphasia therapy for 30 minutes during transcranial direct current stimulation
Study NCT00808392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b vaccine
Description: 3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
Study NCT00808392 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Haemophilus influenzae type b vaccine
Description: 3 doses one month apart of Haemophilus influenzae type b vaccine.
Study NCT03440073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Concept Intervention
Description: The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
Study NCT03440073 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Mulligan Concept Treatment
Description: The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
Study NCT03509818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric exercise
Description: acute plyometric exercise
Study NCT03509818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: acute aerobic exercise
Study NCT03729986 — intervention group
Intervention type: OTHER
Intervention: Loaded inspiratory muscle test
Description: Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
Study NCT02996422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based water campaign
Description: Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
Study NCT02996422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community cooking classes
Description: Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
Study NCT00641108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADAM SPECT plus Cognitive Therapy
Study NCT00641108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADAM SPECT plus No Therapy
Study NCT01998061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitor
Description: Arm A
Study NCT01998061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitor with chemotherapy
Description: Arm B
Study NCT02520492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive method of ICP measurements (Elios)
Study NCT00606645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb2513
Description: Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
Study NCT02491177 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cMM
Description: Home visits from community mentor mothers
Study NCT02491177 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Messaging
Description: Text messages received on mobile phone
Study NCT00152204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine used for IPTi
Description: Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
Study NCT00152204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPTi
Description: Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
Study NCT01776853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Study NCT01776853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Study NCT01776853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructans
Study NCT04620889 — intervention group
Intervention type: DEVICE
Intervention: AV Access
Description: Arteriovenous shunting for blood access.
Study NCT04620889 — intervention group
Intervention type: DEVICE
Intervention: PVP
Description: Bypass or reconstruction of diseased or occluded blood vessels
Study NCT01534481 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Donor Milk
Description: Donor milk provided by the Human Milk Banking Association of North America
Study NCT01534481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Preterm Formula
Description: Preterm Formula determined by center practice.
Study NCT03886493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
Study NCT02639247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study NCT02639247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily without regard to food
Study NCT00435630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LapSim training
Description: complete curriculum training on LapSim surgical simulator
Study NCT00484341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Study NCT00484341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose NGR-hTNF
Description: NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Study NCT00484341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
Study NCT02054975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2 + vitamin D3
Description: higher dose vitamin D
Study NCT02054975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: lower dose vitamin D
Study NCT03330444 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial biopsy and endometrial fluid collection
Description: On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
Study NCT02930707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
Study NCT02930707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
Study NCT04176107 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Informative video
Description: Exposure to informative video before cesarean delivery
Study NCT03763734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study NCT03763734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study NCT05225519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-sleeved white shirt impregnated with a long-infrared irradiation
Description: Usage of an experimental shirt for a period of 12 weeks.
Study NCT05225519 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: long-sleeved white shirt
Description: Usage of an experimental shirt for a period of 12 weeks.
Study NCT03541278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIT
Description: periareolar intraparenchymal, high volume and ultrasonographic guidance
Study NCT03541278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IM-SLNB
Description: IM-SLNB was performed for IMLN visualized patients
Study NCT01173510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir plus Truvada
Description: Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
Study NCT01173510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
Study NCT02255929 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery
Study NCT00888914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT001
Description: RT001
Study NCT00888914 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Comparator
Description: Vehicle Comparator
Study NCT01336244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0778
Description: capsules containing 50 or 100 mg of GLPG0778
Study NCT01336244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule